MARKET

RXDX

Prometheus Biosciences, Inc.
RXDX
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-28.7594
2388.53
13.67
9,558,822,540.96
Mirador Therapeutics raises over $400 mln in early funding rounds
Mirador Therapeutics raises over $400 mln in early funding rounds. Mirador is focusing on skin, lung and gastrointestinal diseases. Easing inflationary pressures and promising data from drug trials are starting to boost biotech funding market. The company is looking to develop precision medicines for immune-related diseases.
Reuters · 03/21 11:00
BUZZ-BMO Capital says Merck 'not just a Keytruda story anymore', raises rating
Reuters · 10/27/2023 12:16
BREAKINGVIEWS-Roche's $7 bln deal is pricey and partial cure
Reuters · 10/23/2023 15:01
UPDATE 1-Merck beats quarterly sales estimate on top drugs strength
Reuters · 08/01/2023 10:49
EXCLUSIVE-MoonLake Immunotherapeutics explores sale-sources
Reuters · 07/14/2023 19:35
Why Shares of Exscientia Jumped on Wednesday
The Motley Fool · 07/12/2023 20:51
Why Shares of Ventyx Biosciences Rose Monday
The Motley Fool · 07/03/2023 18:09
Is Merck Stock a Top Buy Right Now?
The Motley Fool · 06/19/2023 13:15
More

Webull offers Prometheus Biosciences, Inc. stock information, including NASDAQ: RXDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RXDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RXDX stock methods without spending real money on the virtual paper trading platform.